Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

scPharmaceuticals, Inc. (SCPH) had Revenue of $36.33M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$36.33M
Net Income	$-85.15M
Cost of Goods Sold	$11.36M
Gross Profit	$24.97M
Operating Expenses	$101.11M
Operating Income	$-64.78M
Non-Operating Income/Expense	$-20.37M
Pre-Tax Income	$-85.15M
Normalized Pre-Tax Income	$-85.15M
Income after Taxes	$-85.15M
Income from Continuous Operations	$-85.15M
Consolidated Net Income/Loss	$-85.15M
Normalized Income after Taxes	$-85.15M
EBIT	$-64.78M
EBITDA	$-64.76M
Weighted-Average Shares Outstanding (Basic)	44.52M
Weighted-Average Shares Outstanding (Diluted)	44.52M
Earnings per Share (EPS) (Basic)	$-1.91
Earnings per Share (EPS) (Diluted)	$-1.91
Balance Sheet Financials
Current Assets	$105.85M
Property, Plant, and Equipment	$0.06M
Long-Term Assets	$1.67M
Total Assets	$107.52M
Current Liabilities	$14.88M
Long-Term Debt	$51.35M
Long-Term Liabilities	$79.32M
Total Liabilities	$94.20M
Common Equity	$13.32M
Tangible Shareholders Equity	$13.32M
Shareholders Equity	$13.32M
Common Shares Outstanding	50.10M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-70.54M
Cash Flow from Investing Activities	$29.30M
Cash Flow from Financial Activities	$70.08M
Beginning Cash	$46.81M
End Cash	$75.66M
Increase/Decrease in Cash	$28.84M
Stock-Based Compensation	$5.44M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	7.12
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.79
Debt to Equity Ratio	3.86
Gross Margin	68.73%
Operating Margin	-178.29%
EBIT Margin	-178.29%
EBITDA Margin	-178.23%
Pre-Tax Profit Margin	-234.36%
Profit Margin	-234.36%
Free Cash Flow	$-70.56M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	0.82
Receiveable Turnover	3.10
Days Sales in Receivables	117.75
Return on Equity	-639.25%
Return on Tangible Equity	-639.25%
Return on Assets	-79.19%
Return on Investments	-131.67%
Book Value Per Share	$0.27
Free Cash Flow per Share	$-1.58
Operating Cash Flow per Share	$-1.58

Data from Zacks Investment Research, Inc.